Kim P. Kamdar sold $6 of EVFM
director at Evofem Biosciences, Inc.. 10 shares at an average of $0.62, traded Dec 21, 2023, filed Dec 22, 2023.
Score components
- +15RoleDirector
- 0Trade size$6 at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -40.0%, 3m -75.4%, 6m -83.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-23-045912, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 21, 2023 | SOpen-market sale Common Stock | -10 | $0.62 | $6 | 0 | Dec 22, 2023 |
Related signals
Other insiders at Evofem Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | EVFMsell Evofem Biosciences, Inc. | Yan Zhang CFO | $4 104 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.